2025-10-01 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS), incorporating all the provided information.  The report is in English and provides a concise summary with key data points highlighted.

**Report on Hims & Hers Health Inc. (HIMS)**

**Company Overview:** Hims & Hers Health Inc. is a telehealth company that provides personalized health and wellness solutions to consumers.

**1. Performance vs. S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 277.48%
*   **VOO Cumulative Return:** 71.52%
*   **Absolute Divergence:** 203.4 (HIMS significantly outperformed VOO)
*   **Relative Divergence:** 74.1 (HIMS's outperformance is in the 74.1 percentile range of its historical divergence from VOO)

**Analysis:** HIMS has dramatically outperformed the S&P 500 (VOO) over the period. The relative divergence suggests this level of outperformance is significant compared to its historical performance.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD      | Alpha   | Beta | Cap(B) |
| :----------- | :------- | :------- | :------ | :--- | :------- |
| 2019-2021  | -42.0%   | 74.4%    | -81.0%  | 0.0  | 1.5    |
| 2020-2022  | -19.0%   | 78.6%    | -18.0%  | -0.0 | 1.4    |
| 2021-2023  | -65.0%   | 78.6%    | -67.0%  | -0.1 | 2.0    |
| 2022-2024  | 119.0%   | 79.4%    | 98.0%   | -0.0 | 5.4    |
| 2023-2025  | 282.0%   | 80.8%    | 220.0%  | 0.1  | 12.7   |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows a wide range, with strong growth in recent periods (2022-2025).
*   **MDD:**  Maximum Drawdown is consistently high, indicating significant volatility.
*   **Alpha:**  Alpha is generally negative in the earlier periods but turns strongly positive in the later period (2022-2025), suggesting HIMS is generating excess returns independent of market movements more recently.
*   **Beta:** Beta is relatively low, hovering around 0, indicating that HIMS has been less sensitive to overall market movements.  However, the most recent period (2023-2025) shows a slightly positive Beta, suggesting a slightly increased correlation with the market.
*   **Cap:** The company's capitalization has been growing quickly.

**2. Recent Stock Price Movement**

*   **Current Price:** 57.005
*   **Last Market Data:** Price: 57.0088, Previous Close: 59.12, Change: -3.57
*   **5-day Moving Average:** 55.4829
*   **20-day Moving Average:** 52.1402
*   **60-day Moving Average:** 51.3087

**Analysis:** The stock price is above all three moving averages, indicating an upward trend. The recent price drop (-3.57 from the previous close) suggests a short-term pullback, but the overall trend remains positive.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 64.64 (Approaching overbought territory but not yet there)
*   **PPO:** 1.092 (Positive, indicating an upward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Delta_Previous_Relative_Divergence:** 1.0 (+) (Short-term upward momentum)
*   **Expected Return:** -2.8% (Long-term underperformance vs S&P 500 if investing now)

**Analysis:**  The MRI suggests a relatively low-risk investment environment. The RSI suggests the stock is approaching overbought conditions.  The positive PPO reinforces the upward trend. The negative expected return suggests that while HIMS has outperformed significantly in the past, future returns may not be as strong compared to the S&P 500.  The recent price drop of -3.57 is a notable short-term factor.

**4. Recent News & Significant Events:**

*   **Positive Articles:** Several articles highlight HIMS's outperformance and potential as an investment (e.g., "Hims & Hers Health, Inc. (HIMS) Laps the Stock Market"). The comparison to DOCS (another digital health platform) is relevant.
*   **Insider Selling:** The report of insider selling is a potential concern and should be considered cautiously.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
| :--------- | :--- | :--------- |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2025-08-04 | 0.06 | 0.32 B$   |

**Analysis:**  While there appears to be a typo in dates (two entries for 2025-08-04), the table shows increasing revenue overall. EPS is volatile, but the most recent data suggests a generally positive trend.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :------------ |
| 2025-06-30 | $0.54B   | 76.39%        |
| 2025-03-31 | $0.59B   | 73.50%        |
| 2024-12-31 | $0.48B   | 76.81%        |
| 2024-09-30 | $0.40B   | 79.16%        |
| 2024-06-30 | $0.32B   | 81.30%        |

Capital and Profitability:

| Quarter      | Equity     | ROE     |
| :----------- | :--------- | :------ |
| 2025-06-30 | $0.56B   | 7.55%   |
| 2025-03-31 | $0.55B   | 9.01%   |
| 2024-12-31 | $0.48B   | 5.46%   |
| 2024-09-30 | $0.44B   | 17.18%  |
| 2024-06-30 | $0.36B   | 3.67%   |

**Analysis:** Revenue is consistently increasing, indicating strong growth. Profit margins are very high and relatively stable. Equity is growing, suggesting a healthy financial position. ROE is volatile, with a high peak but has decreased more recently.

**7. Summary and Overall Assessment:**

Hims & Hers Health Inc. (HIMS) has demonstrated significant outperformance compared to the S&P 500, driven by strong revenue growth and high-profit margins. Recent news articles are generally positive, highlighting its momentum. However, the report of insider selling and the recent price drop (-3.57) warrant caution.

*   **Strengths:** High revenue growth, strong profit margins, positive momentum.
*   **Weaknesses:** Insider selling, volatile EPS, and high maximum drawdowns, negative expected return (suggesting future underperformance vs. S&P 500 if investing now).
*   **Valuation:** Analyst consensus is "Hold" with a target price significantly below the current price, suggesting the stock may be overvalued.

**Recommendation:** While HIMS exhibits strong growth characteristics, the analyst consensus, insider selling, and negative expected return suggest caution. Potential investors should carefully consider their risk tolerance and conduct further due diligence before investing. It is important to consider the significant drop of -3.57, potentially signalling a short-term correction. A more conservative approach may be warranted.

